{"slug":"targeted-therapy","tag":"targeted-therapy","variants":["targeted-therapy","targeted therapy"],"description":"People whose work centres on targeted drugs and the biomarkers that select them.","count":38,"kinds":{"person":38},"related":[{"slug":"trialist","tag":"trialist","shared":22},{"slug":"lung","tag":"lung","shared":7},{"slug":"colorectal","tag":"colorectal","shared":5},{"slug":"thyroid","tag":"thyroid","shared":5},{"slug":"clinician-scientist","tag":"clinician-scientist","shared":3},{"slug":"lung-cancer","tag":"lung cancer","shared":3},{"slug":"aml","tag":"aml","shared":2},{"slug":"brain","tag":"brain","shared":2},{"slug":"gist","tag":"gist","shared":2},{"slug":"melanoma","tag":"melanoma","shared":2},{"slug":"paediatric","tag":"paediatric","shared":2},{"slug":"sarcoma","tag":"sarcoma","shared":2}],"records":[{"id":"lu-shun","kind":"person","name":"Shun Lu","route":"/people/lu-shun/","tldr":"A Shanghai lung cancer trialist who has led many Chinese PD-1 and EGFR-TKI phase 3 studies."},{"id":"david-planchard","kind":"person","name":"David Planchard","route":"/people/david-planchard/","tldr":"Gustave Roussy thoracic oncologist on the IFCT board, widely published on BRAF- and EGFR-targeted therapy in lung cancer."},{"id":"suresh-ramalingam","kind":"person","name":"Suresh S. Ramalingam","route":"/people/suresh-ramalingam/","tldr":"Lung cancer medical oncologist who leads Winship Cancer Institute of Emory University and led the FLAURA trial of osimertinib."},{"id":"ross-camidge","kind":"person","name":"D. Ross Camidge","route":"/people/ross-camidge/","tldr":"Led the crizotinib and brigatinib trials that defined ALK-targeted lung cancer therapy."},{"id":"ferdinandos-skoulidis","kind":"person","name":"Ferdinandos Skoulidis","route":"/people/ferdinandos-skoulidis/","tldr":"Led CodeBreaK 100, the trial that made sotorasib the first approved KRAS inhibitor, and showed STK11/KEAP1 co-mutations blunt immunotherapy."},{"id":"scott-kopetz","kind":"person","name":"Scott Kopetz","route":"/people/scott-kopetz/","tldr":"Led BEACON and BREAKWATER, the trials that gave BRAF-mutant colorectal cancer its first targeted therapies."},{"id":"lipika-goyal","kind":"person","name":"Lipika Goyal","route":"/people/lipika-goyal/","tldr":"Led the futibatinib trial and defined how FGFR2-driven bile duct cancers become resistant to targeted drugs."},{"id":"reinhard-dummer","kind":"person","name":"Reinhard Dummer","route":"/people/reinhard-dummer/","tldr":"Swiss dermato-oncologist who led COLUMBUS and the neoadjuvant talimogene laherparepvec studies."},{"id":"ingo-mellinghoff","kind":"person","name":"Ingo K. Mellinghoff","route":"/people/ingo-mellinghoff/","tldr":"Led INDIGO, the trial that made vorasidenib the first targeted therapy for low-grade IDH-mutant glioma."},{"id":"george-demetri","kind":"person","name":"George D. Demetri","route":"/people/george-demetri/","tldr":"Led the imatinib trial in GIST that proved a targeted drug could melt away a solid tumour, and every GIST kinase inhibitor since."},{"id":"lori-wirth","kind":"person","name":"Lori J. Wirth","route":"/people/lori-wirth/","tldr":"Led LIBRETTO-001 in thyroid cancer, which made selpercatinib the first RET-selective drug approved for RET-driven tumours."},{"id":"marcia-brose","kind":"person","name":"Marcia S. Brose","route":"/people/marcia-brose/","tldr":"Led DECISION, the trial that made sorafenib the first approved targeted drug for radioiodine-refractory thyroid cancer."},{"id":"alexander-perl","kind":"person","name":"Alexander E. Perl","route":"/people/alexander-perl/","tldr":"Led ADMIRAL, which made gilteritinib the standard for relapsed FLT3-mutant AML."},{"id":"ghayas-issa","kind":"person","name":"Ghayas C. Issa","route":"/people/ghayas-issa/","tldr":"First author of the revumenib trial that created the menin inhibitor class for acute leukaemia."},{"id":"john-byrd","kind":"person","name":"John C. Byrd","route":"/people/john-byrd/","tldr":"Led the ibrutinib trials that turned CLL from a chemotherapy disease into one treated with pills."},{"id":"keunchil-park","kind":"person","name":"Keunchil Park","route":"/people/keunchil-park/","tldr":"Korean lung cancer specialist who led CHRYSALIS, the first human study of amivantamab, whose exon 20 insertion cohort earned the drug its first approval."},{"id":"alice-shaw","kind":"person","name":"Alice T. Shaw","route":"/people/alice-shaw/","tldr":"Lung cancer doctor whose trials at Massachusetts General Hospital showed that crizotinib works in ROS1-rearranged lung cancer and defined how ALK-positive tumours become resistant to targeted drugs."},{"id":"robert-doebele","kind":"person","name":"Robert C. Doebele","route":"/people/robert-doebele/","tldr":"Lung cancer researcher who led the pooled analysis showing that entrectinib shrinks NTRK fusion-positive tumours of many kinds, and who studied how ROS1 and NTRK cancers escape targeted drugs."},{"id":"gregory-riely","kind":"person","name":"Gregory J. Riely","route":"/people/gregory-riely/","tldr":"Lung cancer doctor who led PHAROS, the trial that brought the encorafenib and binimetinib pair to BRAF V600E-mutant lung cancer."},{"id":"paul-paik","kind":"person","name":"Paul K. Paik","route":"/people/paul-paik/","tldr":"Lung cancer doctor who was lead author of VISION, the trial that established tepotinib for lung cancers with MET exon 14 skipping mutations."},{"id":"michael-heinrich","kind":"person","name":"Michael C. Heinrich","route":"/people/michael-heinrich/","tldr":"Oregon physician-scientist who showed that the KIT mutation type in a GIST predicts how well imatinib works, discovered PDGFRA mutations in the tumours without KIT mutations, and led NAVIGATOR, which established avapritinib for PDGFRA D842V disease."},{"id":"jan-burger","kind":"person","name":"Jan A. Burger","route":"/people/jan-burger/","tldr":"Leukaemia specialist who was lead author of RESONATE-2, the trial that made ibrutinib a first-line treatment for chronic lymphocytic leukaemia in older patients."},{"id":"jose-baselga","kind":"person","name":"José Baselga","route":"/people/jose-baselga/","tldr":"Spanish oncologist who helped develop trastuzumab, pertuzumab and everolimus for breast cancer, and was lead author of BOLERO-2, which established everolimus plus exemestane for hormone-receptor-positive disease."},{"id":"paul-chapman","kind":"person","name":"Paul B. Chapman","route":"/people/paul-chapman/","tldr":"New York melanoma doctor who was lead author of BRIM-3, the trial that showed vemurafenib lengthens survival in BRAF-mutant melanoma and launched targeted therapy for the disease."},{"id":"aleksandar-sekulic","kind":"person","name":"Aleksandar Sekulic","route":"/people/aleksandar-sekulic/","tldr":"Mayo Clinic dermatologist who led ERIVANCE, the trial that established vismodegib, the first Hedgehog pathway inhibitor, for advanced basal cell carcinoma."},{"id":"rossella-elisei","kind":"person","name":"Rossella Elisei","route":"/people/rossella-elisei/","tldr":"Pisa endocrinologist who led EXAM, the trial that established cabozantinib for progressive medullary thyroid cancer, and who has studied RET mutations in the disease for decades."},{"id":"julien-hadoux","kind":"person","name":"Julien Hadoux","route":"/people/julien-hadoux/","tldr":"Paris endocrine oncologist who was lead author of LIBRETTO-531, the trial that showed the selective RET inhibitor selpercatinib beats older kinase inhibitors as first treatment for advanced medullary thyroid cancer."},{"id":"vivek-subbiah","kind":"person","name":"Vivek Subbiah","route":"/people/vivek-subbiah/","tldr":"Early-phase trialist who led the study showing dabrafenib and trametinib work in BRAF-mutant anaplastic thyroid cancer, the first approved treatment for that disease, and many of the RET inhibitor trials."},{"id":"susana-banerjee","kind":"person","name":"Susana Banerjee","route":"/people/susana-banerjee/","tldr":"London gynaecological oncologist who led RAMP 201, the trial that established the avutometinib and defactinib combination for recurrent KRAS-mutant low-grade serous ovarian cancer."},{"id":"eric-jonasch","kind":"person","name":"Eric Jonasch","route":"/people/eric-jonasch/","tldr":"Houston oncologist who led the trial that established belzutifan, the first drug for the tumours of von Hippel-Lindau disease, including kidney cancers, pancreatic tumours and haemangioblastomas."},{"id":"darren-hargrave","kind":"person","name":"Darren R. Hargrave","route":"/people/darren-hargrave/","tldr":"London paediatric neuro-oncologist who led the trial showing that dabrafenib and trametinib work in children with BRAF V600-mutant high-grade glioma."},{"id":"giles-robinson","kind":"person","name":"Giles W. Robinson","route":"/people/giles-robinson/","tldr":"Memphis paediatric neuro-oncologist who led the study showing that the Hedgehog inhibitor vismodegib helps only adults and older children whose medulloblastoma belongs to the SHH subgroup, an early example of subgroup-directed brain tumour therapy."},{"id":"andrew-wagner","kind":"person","name":"Andrew J. Wagner","route":"/people/andrew-wagner/","tldr":"Boston sarcoma doctor who first showed that mTOR inhibitors shrink perivascular epithelioid cell tumours and then led AMPECT, the trial that made nab-sirolimus the first approved treatment for these rare cancers."},{"id":"jennifer-chan","kind":"person","name":"Jennifer A. Chan","route":"/people/jennifer-chan/","tldr":"Boston oncologist who led CABINET, the trial that showed cabozantinib delays progression of advanced neuroendocrine tumours after other treatments have failed."},{"id":"john-strickler","kind":"person","name":"John H. Strickler","route":"/people/john-strickler/","tldr":"Duke oncologist who led MOUNTAINEER, the trial that made tucatinib plus trastuzumab the first approved HER2-directed treatment for colorectal cancer."},{"id":"andrea-sartore-bianchi","kind":"person","name":"Andrea Sartore-Bianchi","route":"/people/andrea-sartore-bianchi/","tldr":"Milan oncologist who was lead author of HERACLES, the first trial to show that HER2-targeted drugs work in HER2-amplified colorectal cancer."},{"id":"salvatore-siena","kind":"person","name":"Salvatore Siena","route":"/people/salvatore-siena/","tldr":"Milan oncologist who co-led HERACLES and was lead author of DESTINY-CRC01, which showed trastuzumab deruxtecan is active in HER2-positive colorectal cancer, and a leader of the anti-EGFR antibody trials in the disease."},{"id":"rona-yaeger","kind":"person","name":"Rona Yaeger","route":"/people/rona-yaeger/","tldr":"New York oncologist who was lead author of the KRYSTAL-1 colorectal report, which showed adagrasib with cetuximab shrinks KRAS G12C-mutant colorectal cancer and led to the combination's approval."}]}